COBALT:奥贝胆酸治疗原发性胆汁性胆管炎的验证性试验——安慰剂对照与外部对照研究
COBALT验证性试验评估奥贝胆酸(OCA)治疗原发性胆汁性胆管炎(PBC)能否改善临床结局。随机对照部分中,OCA组与安慰剂组主要复合终点发生率分别为28.6%与28.9%(HR=1.01,95%CI 0.68-1.51),但存在功能性揭盲与交叉换药;经逆概率删失加权及按治疗分析校正后HR转向有利于OCA。外部对照(n=1,051)加权分析显示,OCA组与非OCA组主要终点发生率分别为10.1%与21.5%(HR=0.39,95%CI 0.22-0.69,P=0.001)。
要点
- 随机对照部分OCA组与安慰剂组主要终点发生率相近(28.6% vs 28.9%,HR=1.01),但存在功能性揭盲与治疗交叉。
- 校正揭盲与交叉后,HR转向有利于OCA。
- 外部对照加权分析中OCA组主要终点发生率低于非OCA组(10.1% vs 21.5%,HR=0.39)。
核心结论
- 随机对照部分的功能性揭盲与治疗交叉(尤其安慰剂组)混杂了OCA相关结局的意向性治疗估计。
- 与真实世界外部对照比较显示,OCA治疗显著降低负面临床结局风险。
- 这些分析证明外部对照数据在验证性试验中的价值,并提示OCA治疗可改善PBC患者的临床结局。
研究设计与样本
- 随机对照试验(RCT)部分:患者随机接受OCA 5-10 mg或安慰剂。
- 外部对照(EC)部分:从美国医疗索赔数据库构建预设倾向评分加权的外部对照组。
- RCT中OCA组n=168,安慰剂组n=166;EC组n=1,051。
主要发现
- RCT意向性治疗分析:主要复合终点发生在OCA组28.6%(n=168)与安慰剂组28.9%(n=166),HR=1.01,95%CI 0.68-1.51。
- RCT中存在功能性揭盲与交叉至商业治疗,尤其见于安慰剂组;采用逆概率删失加权与按治疗分析校正后,HR转向有利于OCA。
- EC加权分析:主要终点发生在OCA组10.1%与非OCA组21.5%,HR=0.39,95%CI 0.22-0.69,P=0.001。
- RCT中未发现新的安全性信号。
关键数值与推荐
- 主要复合终点为至死亡、肝移植、终末期肝病模型评分≥15、难治性腹水或肝失代偿住院的时间。
- RCT主要终点发生率:OCA组28.6%(n=168) vs 安慰剂组28.9%(n=166),HR=1.01,95%CI 0.68-1.51。
- EC加权主要终点发生率:OCA组10.1% vs 非OCA组21.5%,HR=0.39,95%CI 0.22-0.69,P=0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- RCT中存在功能性揭盲与交叉至商业治疗,尤其见于安慰剂组,混杂了意向性治疗估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Obeticholic acid (OCA) treatment for primary biliary cholangitis (PBC) was conditionally approved in the phase 3 POISE trial. The COBALT confirmatory trial assessed whether clinical outcomes in patients with PBC improve with OCA therapy. METHODS: Patients randomized to OCA (5-10 mg) were compared with placebo (randomized controlled trial [RCT]) or external control (EC). The primary composite endpoint was time to death, liver transplant, model for end-stage liver disease score ≥15, uncontrolled ascites, or hospitalization for hepatic decompensation. A prespecified propensity score-weighted EC group was derived from a US healthcare claims database. RESULTS: In the RCT, the primary endpoint occurred in 28.6% of OCA (n = 168) and 28.9% of placebo patients (n = 166; intent-to-treat analysis hazard ratio [HR] = 1.01, 95% confidence interval = 0.68-1.51), but functional unblinding and crossover to commercial therapy occurred, especially in the placebo arm. Correcting for these using inverse probability of censoring weighting and as-treated analyses shifted the HR to favor OCA. In the EC (n = 1,051), the weighted primary endpoint occurred in 10.1% of OCA and 21.5% of non-OCA patients (HR = 0.39; 95% confidence interval = 0.22-0.69; P = 0.001). No new safety signals were identified in the RCT. DISCUSSION: Functional unblinding and treatment crossover, particularly in the placebo arm, confounded the intent-to-treat estimate of outcomes associated with OCA in the RCT. Comparison with the real-world EC showed that OCA treatment significantly reduced the risk of negative clinical outcomes. These analyses demonstrate the value of EC data in confirmatory trials and suggest that treatment with OCA improves clinical outcomes in patients with PBC.
引用
- Kowdley KV, Hirschfield GM, Coombs C, et al. COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. Am J Gastroenterol. 2024. PMID: 39140490. doi:10.14309/ajg.0000000000003029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。